ArticleAdvances in radiation oncology2026
Hematological Toxicity and Bone Marrow Dose-Volume Effects in Chemotherapy-Naïve Patients Treated With Whole Pelvic and Para-aortic Lymph Node Radiation Therapy For Pathologic Pelvic Lymph Node-Positive Prostate Cancer.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03079323 (Phase II Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer Using Arc Therapy (IMAT/VMAT)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Whole pelvic radiation therapy combined with androgen-deprivation therapy improves prostate cancer-specific survival in pathologic pelvic lymph node-positive prostate cancer. Elective para-aortic radiation therapy may further improve clinical outcomes and is under investigation in the Para-Aortic Radiotherapy (PART) study (NCT03079323). This study investigated the effect of whole pelvic radiation therapy plus PART on hematological toxicity (HemT). Methods and Materials: HemT and bone marrow (BM) dose-volume relationships were analyzed in the first 75 PART patients enrolled in the University Hospitals Leuven, all receiving 24 months of androgen-deprivation therapy or antiandrogen therapy. Hematological changes were assessed longitudinally. Associations were analyzed using linear models for repeated measures, with false discovery rate correction. Results: At 57-months median follow-up (median age, 66 years), no HemT caused treatment interruption. All blood parameters declined significantly after radiation therapy (all Conclusions: Extended-field radiation therapy is clinically well tolerated in chemotherapy-naïve pathologic pelvic lymph node-positive prostate cancer patients, with no toxicity-related treatment interruptions. However, persistent lymphopenia was observed. Dose-dependent association between low-dose BM irradiation (V3-V10) and late ALC decline supports further research into BM-sparing techniques to reduce long-term toxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.